Skip to main content
. Author manuscript; available in PMC: 2023 Jun 12.
Published in final edited form as: Onco Ther. 2022;9(2):43–55. doi: 10.1615/oncotherap.v9.i2.50

TABLE 1:

NCTs utilizing pectin

NCT no. Title Status Intervention Characteristics
N/A Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study Completed Oral MCP Prospective pilot study
NCT02575404 Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients with Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma Completed Belapectin (GR-MD-02) + pembrolizumab Interventional phase I
NCT01681823 Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Cirtus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA Completed PectaSol-C modified citrus pectin Interventional Phase II
NCT02270268 Therapeutic Effects of Pectin Supplementation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Completed Pectin Interventional Phase III